Based on the Astrana Health Inc stock forecast from 6 analysts, the average analyst target price for Astrana Health Inc is USD 58.08 over the next 12 months. Astrana Health Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Astrana Health Inc is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Astrana Health Inc’s stock price was USD 54.66. Astrana Health Inc’s stock price has changed by -12.60% over the past week, -4.16% over the past month and 0% over the last year.
No recent analyst target price found for Astrana Health Inc
No recent average analyst rating found for Astrana Health Inc
Company Overview Astrana Health Inc
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California. Address: 1668 S. Garfield Avenue, Alhambra, CA, United States, 91801 Read Less
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary ...Read More
Frequently Asked Questions About Astrana Health Inc (ASTH) Stock
Based on ratings from 6 analysts Astrana Health Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 10 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on ASTH's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ASTH is USD 58.08 over the next 12 months. The maximum analyst target price is USD 70 while the minimum anlayst target price is USD 44.
ASTH stock's Price/Earning ratio is 40.19.
Our analysis grades ASTH stock's Price / Earning ratio at F. This means that ASTH stock's Price/Earning ratio is above 56.00000000000001% of the stocks in the Medical Care Facilities sector in the NSD exchange.
Based on this ASTH may be a overvalued for its sector.
The last closing price of ASTH's stock was USD 54.66.
The most recent market capitalization for ASTH is USD 2.64B.
Based on targets from 6 analysts, the average taret price for ASTH is projected at USD 58.08 over the next 12 months.
This means that ASTH's stock price may go up by +6.26% over the next 12 months.
We can't find any ETFs which contains Astrana Health Inc's stock.
As per our most recent records Astrana Health Inc has 1,800 Employees.
Astrana Health Inc's registered address is 1668 S. Garfield Avenue, Alhambra, CA, United States, 91801.
You can get more information about it from Astrana Health Inc's website at https://www.astranahealth.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Astrana Health Inc (ASTH) Stock
Based on ratings from 6 analysts Astrana Health Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 10 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on ASTH's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ASTH is USD 58.08 over the next 12 months. The maximum analyst target price is USD 70 while the minimum anlayst target price is USD 44.
ASTH stock's Price/Earning ratio is 40.19.
Our analysis grades ASTH stock's Price / Earning ratio at F. This means that ASTH stock's Price/Earning ratio is above 56.00000000000001% of the stocks in the Medical Care Facilities sector in the NSD exchange.
Based on this ASTH may be a overvalued for its sector.
The last closing price of ASTH's stock was USD 54.66.
The most recent market capitalization for ASTH is USD 2.64B.
Based on targets from 6 analysts, the average taret price for ASTH is projected at USD 58.08 over the next 12 months.
This means that ASTH's stock price may go up by +6.26% over the next 12 months.
We can't find any ETFs which contains Astrana Health Inc's stock.
As per our most recent records Astrana Health Inc has 1,800 Employees.
Astrana Health Inc's registered address is 1668 S. Garfield Avenue, Alhambra, CA, United States, 91801.
You can get more information about it from Astrana Health Inc's website at https://www.astranahealth.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ASTH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
